Navigation Links
Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives
Date:12/3/2008

and advancing our preclinical pipeline, while maintaining a strong balance sheet. We have established important commercial agreements in the non-therapeutic aspects of our technology with Dow Agrosciences in plant agriculture and Sigma-Aldrich Corporation in research reagents. We also have agreements with Genentech and Pfizer in cell-line engineering. We plan to establish strategic partnerships around our therapeutic programs at points of value inflection and expect 2009 to be another year of significant accomplishments for Sangamo."

Mr. Lanphier continued, "We are pursuing a broad development program for our lead ZFP Therapeutic(TM), SB-509, an activator of vascular endothelial growth factor (VEGF) with three Phase 2 clinical trials ongoing for the treatment of diabetic neuropathy (DN) and one to evaluate its use in the treatment of amyotrophic lateral sclerosis (ALS). We have also advanced our preclinical pipeline and expect to file Investigational New Drug (IND) application for the first of our ZFN-based therapeutic programs for HIV/AIDS before the end of 2008.

"We are very pleased by the progress of our non-therapeutic collaborations this year. Our partner Sigma-Aldrich successfully launched the CompoZr brand of ZFN-based gene editing tools and we look forward to the increased interest and further validation of the technology that this broadening of the user-base will bring. We also transitioned ahead of schedule into the commercial phase of our collaboration with Dow AgroSciences (DAS) to apply our ZFP technology for plant agriculture and expect DAS to begin to sublicense the technology in that industry. The success of these activities is key to further enhancing the market-leading presence for our technology. We believe that our progress in advancing our technology platform, which is unique in its generation of novel, highly differentiated therapies and products, will create interest among potential pharmace
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
2. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
3. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
7. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
8. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
11. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... , Sept. 12, 2014 Research ... "Global Diclofenac Industry Report 2014" report to ... Report 2014 is a professional and in-depth study on ... The report provides a basic overview of ... structure. The diclofenac market analysis is provided for the ...
(Date:9/12/2014)... -- Research and Markets  has announced the addition of ... & Forecast - Worldwide" report to their offering. ... women in both the developed and developing world. Worldwide Breast ... 2013. United States is the leading ... is expected to maintain its 2nd position in the ...
(Date:9/12/2014)... -- According to the new research report "Point-Of-Care Diagnostics ... Diseases Testing Kits, Cardiac & Tumor Markers), by End ... Prescription Based - Global Forecast to 2018" published by ... the forecast period of 2013 to 2018. The market ... from 2013 to 2018, to reach $27.5 billion by ...
Breaking Medicine Technology:Global Diclofenac Industry Report 2014 2Breast Cancer Screening (Mammography, MRI & Ultrasound) Market & Forecast - Worldwide 2Breast Cancer Screening (Mammography, MRI & Ultrasound) Market & Forecast - Worldwide 3Breast Cancer Screening (Mammography, MRI & Ultrasound) Market & Forecast - Worldwide 4Point-Of-Care Diagnostic Market Worth $27.5 Billion by 2018 2Point-Of-Care Diagnostic Market Worth $27.5 Billion by 2018 3Point-Of-Care Diagnostic Market Worth $27.5 Billion by 2018 4
... GoodRx today announced that it has created ... with accurate drug prices from virtually every U.S. pharmacy. GoodRx, ... iphone app , allows consumers to compare drug prices, which ... coupons and savings tips. Consumers simply enter ...
... (NASDAQ: HALO ) today announced the completion of ... stock, including 1,020,000 shares sold pursuant to the full exercise ... of the shares were offered by Halozyme at a price ... Halozyme from this offering were approximately $81.8 million, after deducting ...
Cached Medicine Technology:GoodRx™ Brings Price Transparency to Prescription Drugs 2GoodRx™ Brings Price Transparency to Prescription Drugs 3GoodRx™ Brings Price Transparency to Prescription Drugs 4Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock 2Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock 3
(Date:9/13/2014)... Va. (PRWEB) September 13, 2014 Happiness is ... to healthier living and achieving goals. That's what LWell ... pleased to announce that Stephens, a life coach who has ... was a teenager, will present her "Happiness is a Choice" ... 6:30 p.m. , This event is being offered ...
(Date:9/13/2014)... MD (PRWEB) September 13, 2014 Deaf Awareness ... The Hearing and Speech Agency hosts a week-long ... Sign Language (ASL) as the main form of communication. ... the schedule includes an ASL film night, a yoga class, ... open to the entire community. , The schedule is as ...
(Date:9/13/2014)... (PRWEB) September 13, 2014 Motion Graphics artist ... new transition pack entitled TransPack Volume 2 exclusively for Final ... fun way to transition from one clip to the next.” ... can never have too many transition options and TransPack Volume ... TransPack Volume 2 is a package of 30 thematic transitions ...
(Date:9/13/2014)... September 13, 2014 Although it’s cooled ... into mosquito high season are the state’s southern cities ... areas. With a rise in mosquitoes carrying West ... a partnership with Dixie State University’s Dr. Barnum and ... a product called NutriVex. , NutriVex is in its ...
(Date:9/12/2014)... As low testosterone lawsuit claims continue ... two of the U.S. Food & Drug Administration (FDA) ... to discuss controversial public health issues surrounding testosterone replacement ... and the Drug Safety and Risk Management Advisory Committee ... population for testosterone replacement therapy and the potential risk ...
Breaking Medicine News(10 mins):Health News:“Happiness is a Choice” Life Coaching Seminar Open to Community 2Health News:“Happiness is a Choice” Life Coaching Seminar Open to Community 3Health News:Baltimore Nonprofit Celebrates Deaf Awareness Week 2Health News:Baltimore Nonprofit Celebrates Deaf Awareness Week 3Health News:Today a new TransPack Volume 2 transition was announced from Pixel Film Studios for Final Cut Pro X. 2Health News:Dixie State University Partners with Utah Marketing Firm and the SW Mosquito Abatement and Control District for Product Testing 2Health News:Dixie State University Partners with Utah Marketing Firm and the SW Mosquito Abatement and Control District for Product Testing 3Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 2Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 3Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 4Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 5
... Organisation (WHO) Monday hailed the progress of governments of Western ... region needed greater effort to effectively control the disease. ... of detecting at least 70 percent of TB cases and ... Maaren, regional adviser for the health body's TB programme. ...
... miniature robot that can be inserted through an incision ... body. ,Researchers from Ritsumeikan University and the ... that is controlled remotely once placed inside the body. ... centimeters (0.79 inches) in length and one in diameter. ...
... that some patients who complete bariatric surgery can develop ... deficiency, called Wernicke encephalopathy. , The researchers ... about their conclusions by extensive survey of data relating ... surgery. , The syndrome - Wernicke encephalopathy ...
... inhaled anesthetics increase the number of amyloid plaques in ... of neurodegenerative diseases like Alzheimer's. ,Roderic Eckenhoff, ... Pennsylvania's Department of Anesthesia and Critical Care, and his ... edition of Neurobiology of Aging. ,Every year ...
... hardly 29 per cent of the asthmatic children surveyed had ... as a dangerous trend for not vaccinating their kids against ... officials have warned. ,Actually it has been warned ... fall victims to pneumonia or acute respiratory disease. Inactivated flu ...
... possibly hazardous chemicals called polybrominated diphenyl ethers (PBDEs). The ... and Technology and the Environmental Protection Agency of the ... clear how dangerous these PBDEs are, though some types ... is strikingly similar to that of PCBs, which are ...
Cached Medicine News:Health News:WHO Calls for Greater Efforts to Fight TB 2Health News:Inhaled Anesthetics Accelerate the Onset of Neurodegenerative Diseases Like Alzheimer's 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: